Skip to main content

Table 6 Sensitivity of the adjusted CET for ultra-orphans to the R&D and other life-cycle costs assumption.

From: Establishing a reasonable price for an orphan drug

 

All costs decrease in the same proportion than the R&D cost

Only R&D costs decrease for ultra-orphan drugs

Orphan cut-off point

£37,534

£39,260

Ultra-orphan cut-off point

£938,358

£981,507

  1. Base case estimates are shown in italics